Generated by AI
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company focused on developing and commercializing products for medical and aesthetic skin conditions. The company currently works on topical dermatologic solutions that leverage its proprietary technology platform to target a range of skin disorders and cosmetic applications. Its product pipeline includes treatments designed for conditions such as acne, psoriasis, rosacea, and hyperhidrosis, as well as needle-free intradermal delivery approaches for aesthetic uses. Dermata Therapeutics also operates in the direct-to-consumer skincare market through the Tome brand, reflecting its broader emphasis on skin renewal and everyday dermatologic care. Headquartered in San Diego, California, Dermata Therapeutics serves as a specialized participant in the dermatology market, combining pharmaceutical development with consumer skincare products aimed at skin health and appearance.
Website3525 Del Mar Heights Rd.
San Diego, CA, 92130
United States
The latest articles about DRMA.
- Dermata generates product revenue following the launch of its first commercial product,Tome™ Foundational Treatment,
Summary of Oct 16's posts. Generated by AI.
Summary of Oct 16's posts. Generated by AI.
- Tome Clearing Treatment is Dermata's second once-weekly skincare product under its Tome brand -- Tome Clearing
Summary of Oct 16's posts. Generated by AI.
Investors talking about DRMA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.